ImageneBio Valuation
| IMA Stock | 7.04 0.05 0.71% |
At this time, the firm appears to be fairly valued. ImageneBio retains a regular Real Value of USD6.82 per share. The prevalent price of the firm is USD7.04. Our model calculates the value of ImageneBio from evaluating the firm fundamentals such as Operating Margin of (5.01) %, shares owned by institutions of 33.98 %, and Current Valuation of 111.51 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ImageneBio's valuation include:
Fairly Valued
Today
Please note that ImageneBio's price fluctuation is slightly risky at this time. Calculation of the real value of ImageneBio is based on 3 months time horizon. Increasing ImageneBio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ImageneBio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImageneBio Stock. However, ImageneBio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.04 | Real 6.82 | Hype 7.2 | Naive 7.42 |
The real value of ImageneBio Stock, also known as its intrinsic value, is the underlying worth of ImageneBio Company, which is reflected in its stock price. It is based on ImageneBio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ImageneBio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ImageneBio helps investors to forecast how ImageneBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImageneBio more accurately as focusing exclusively on ImageneBio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ImageneBio's intrinsic value based on its ongoing forecasts of ImageneBio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ImageneBio's closest peers. If more than one evaluation category is relevant for ImageneBio we suggest using both methods to arrive at a better estimate.
ImageneBio Cash |
|
ImageneBio Total Value Analysis
ImageneBio is currently expected to have company total value of 111.51 M with market capitalization of 91.69 M, debt of 7.52 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the ImageneBio fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
111.51 M | 91.69 M | 7.52 M |
ImageneBio Investor Information
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.33. ImageneBio had not issued any dividends in recent years. The entity had 1:12 split on the 28th of July 2025. Based on the analysis of ImageneBio's profitability, liquidity, and operating efficiency, ImageneBio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.ImageneBio Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of ImageneBio suggests not a very effective usage of assets in February.ImageneBio Profitability Analysis
Considering ImageneBio's profitability and operating efficiency indicators, ImageneBio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess ImageneBio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-12-31 | Previous Quarter -2.8 M | Current Value -24.8 M | Quarterly Volatility 6.9 M |
For ImageneBio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImageneBio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImageneBio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImageneBio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImageneBio over time as well as its relative position and ranking within its peers.
ImageneBio Earnings per Share Projection vs Actual
By analyzing ImageneBio's earnings estimates, investors can diagnose different trends across ImageneBio's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for ImageneBio is based on EPS before non-recurring items and includes expenses related to employee stock options.ImageneBio Ownership Allocation
The market capitalization of ImageneBio is USD91.69 Million. 30% of ImageneBio outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.ImageneBio Profitability Analysis
The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ImageneBio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ImageneBio and how it compares across the competition.
About ImageneBio Valuation
The stock valuation mechanism determines ImageneBio's current worth on a weekly basis. Our valuation model uses a comparative analysis of ImageneBio. We calculate exposure to ImageneBio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ImageneBio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4 M | 4.2 M | |
| Pretax Profit Margin | (9.40) | (9.87) | |
| Operating Profit Margin | (9.51) | (9.99) | |
| Net Loss | (9.40) | (9.87) | |
| Gross Profit Margin | 0.80 | 0.84 |
ImageneBio Current Valuation Indicators
Valuation refers to the process of determining the present value of ImageneBio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ImageneBio we look at many different elements of the entity such as ImageneBio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ImageneBio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ImageneBio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ImageneBio's worth.Complementary Tools for ImageneBio Stock analysis
When running ImageneBio's price analysis, check to measure ImageneBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImageneBio is operating at the current time. Most of ImageneBio's value examination focuses on studying past and present price action to predict the probability of ImageneBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImageneBio's price. Additionally, you may evaluate how the addition of ImageneBio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |